Associate Director, Translational Medicine and Nonclinical Development

Blue Rock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary CELL+GENE™ platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases.

Founded in 2016, Blue Rock is at the forefront of the convergence of cell biology and genetic engineering. Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.

What Are We Doing?

Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies.

We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options.

Blue Rock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique CELL+GENE™ platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines that address large patient populations suffering from neurological, cardiovascular, and immunology diseases.

The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel CELL+GENE™ platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.

We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.

It continues to be an exciting time for Blue Rock Therapeutics as the company advances cutting edge cellular therapies to positively impact patients’ lives across multiple disease areas.

The Associate Director, TMND, will be expected to take on a highly visible role with internal and external stakeholders through the management of biomarker endpoints, including digital health readouts, leveraged in Blue Rock’s clinical development programs. The Associate Director of Translational Medicine will leverage their expertise across multiple therapeutic areas including neurology and ophthalmology to advance the company’s development pipeline by working closely with program leads and other subject matter experts.

The position will be based in Cambridge, Massachusetts.

As a critical member of the team, the Associate Director of TMND will leverage their expertise to:

• Develop translational biomarker strategies designed to support clinical development plans, the regulatory path, and product commercialization.
• Partner with Research to discover and characterize novel biomarker endpoints in preclinical studies.
• Develop biomarker methods and analytically validate biomarkers for…